The role of taxanes in the treatment of breast cancer is becoming increasingly important. In clinical practice, the taxanes are now standard therapy in both early-stage and metastatic breast cancer. Since the 1990s, multiple randomized clinical trials have been evaluating the efficacy of taxanes in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. Pre-existing published guidelines for the use of taxanes in the management of metastatic breast cancer are available. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. For this task, the panel used the adapte process, which is a systematic process of guideline adaptation developed by the adapte Collaboration. The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated or -resistant patients, and patients overexpressing the human epidermal growth factor receptor 2. Potential toxicities and benefits in terms of time to progression, progression-free survival, overall survival, and quality of life were also considered.
Share and Cite
MDPI and ACS Style
King, K.M.; Lupichuk, S.; Baig, L.; Webster, M.; Basi, S.; Whyte, D.; Rix, S.
Optimal Use of Taxanes in Metastatic Breast Cancer. Curr. Oncol. 2009, 16, 8-20.
King KM, Lupichuk S, Baig L, Webster M, Basi S, Whyte D, Rix S.
Optimal Use of Taxanes in Metastatic Breast Cancer. Current Oncology. 2009; 16(3):8-20.
King, Karen M., S. Lupichuk, L. Baig, M. Webster, S. Basi, D. Whyte, and S. Rix.
2009. "Optimal Use of Taxanes in Metastatic Breast Cancer" Current Oncology 16, no. 3: 8-20.
Article Access Statistics
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.